A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Last updated: May 21, 2025
Sponsor: Vertex Pharmaceuticals Incorporated
Overall Status: Active - Not Recruiting

Phase

1/2

Condition

Diabetes And Hypertension

Diabetes Prevention

Diabetes Mellitus Types I And Ii

Treatment

VX-264

Clinical Study ID

NCT05791201
VX22-264-101
2024-515583-32-00
2022-003318-35
  • Ages 18-65
  • All Genders

Study Summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

Clinical history of T1D with greater than or equal to (>=) 5 years duration Participant is on a stable diabetic treatment Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Exclusion

Key Exclusion Criteria:

Prior islet cell transplant, organ transplant, or cell therapy

Study Design

Total Participants: 7
Treatment Group(s): 1
Primary Treatment: VX-264
Phase: 1/2
Study Start date:
May 16, 2023
Estimated Completion Date:
May 29, 2026

Connect with a study center

  • University of Alberta, Edmonton

    Edmonton,
    Canada

    Site Not Available

  • Montreal Clinical Research Institute

    Montreal,
    Canada

    Site Not Available

  • Toronto General Hospital (TGH)

    Toronto,
    Canada

    Site Not Available

  • Vancouver General Hospital

    Vancouver,
    Canada

    Site Not Available

  • Dresden Center for Islet Transplantation

    Dresden,
    Germany

    Site Not Available

  • IRCCS Ospedale San Raffaele

    Milan,
    Italy

    Site Not Available

  • Leiden University

    Leiden,
    Netherlands

    Site Not Available

  • Hopiteaux Universitaires de Geneve

    Geneve,
    Switzerland

    Site Not Available

  • Churchill Hospital

    Headington,
    United Kingdom

    Site Not Available

  • Royal Victoria Infirmary

    Newcastle Upon Tyne,
    United Kingdom

    Site Not Available

  • UHealth Diabetes Research Institute

    Miami, Florida 33136
    United States

    Site Not Available

  • University of Chicago

    Chicago, Illinois 60637
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • University of Pittsburgh Medical Center Montefiore

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • University of Wisconsin

    Madison, Wisconsin 53792
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.